In the “new normal” of treating cancer patients during COVID-19, when do you decide to start treatment or pause it? Narjust Duma, MD, a thoracic oncologist at the University of Wisconsin, Madison, shares how she makes those decisions in partnership with her lung cancer patients and how the discussions are complicated by the fear and uncertainty around the pandemic.
Later in the podcast, Dr. Duma and podcast host David H. Henry, MD, of Pennsylvania Hospital, Philadelphia, explore how telehealth changes patient encounters, use of liquid biopsies to keep patients out of the hospital, and the importance of checking in with mentees.
Disclosures
Dr. Henry reported having no financial disclosures relevant to this episode. Dr. Duma reported having no financial disclosures relevant to this episode.
* *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter: @ilanayurkiewicz
04/09/20 • 33 min
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/blood-and-cancer-197219/covid-19-and-lung-cancer-the-decision-to-delay-treatment-19337344"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to covid-19 and lung cancer: the decision to delay treatment on goodpods" style="width: 225px" /> </a>
Copy